Clinical trials for ER/PR positive breast cancer

 

Trial name

 

Title of clinical trial

 

Hyperlink

 

G1T38

 

A trial using a CDK 4/6 inhibitor in combination with fulvestrant in hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer.
Open to men and women.

 

Clinical Trials Information

 

AIPAC

 

A study in hormone receptor-positive metastatic breast carcinoma patients receiving IMP321 or placebo in addition to a standard chemotherapy treatment regimen of paclitaxel.
Open to women.

 

Clinical Trials Information

 

GSK525762

 

A study to evaluate the safety of GSK525762 when taken with fulvestrant in subjects with estrogen receptor positive breast cancer.
Open to women.

 

Clinical Trials Information

 

STEM

 

A trial assessing SFX-01 in combination with aromatase inhibitors (AIs), tamoxifen and fulvestrant in metastatic breast cancer.
Open to men & women.

 

Clinical Trials Information

 

CORE

 

A randomised controlled trial, which includes breast, prostate or non-small cell lung primary cancer and extra cranial oligometastases suitable for stereotactic body radiotherapy.

 

Clinical Trials Information

 

B-AHEAD 3

 

A randomised trial of intermittent energy restriction and resistance exercise in women receiving chemotherapy for advanced breast cancer.
Open to women.

 

Clinical Trials Information

 

PIPA

 

A study looking at taselisib and palbociclib for breast cancer with a mutation in the PIK3CA gene that has stopped responding to treatment.
Open to men & women.

 

Clinical Trials Information

 

Plasma Match

 

A trial carrying out plasma based molecular profiling of advanced breast cancer to inform therapeutic choices.
Open to women.

 

Clinical Trials Information